Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

被引：1
|
作者：
Chatterjee, Anuja
Van de Wetering, Gijs
Goeree, Ron
Desbois, Anne Marie
Manzi, Patricia
Manzoor, Beenish S.
Owen, Carolyn
Sail, Kavita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China
    Li, Mengya
    Zhong, Xiaoyan
    Zhang, Chengbin
    Luo, Hongli
    Luo, Li
    Huang, Yilan
    Jiang, Longyang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [12] COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
    Huntington, S. F.
    Strunz-McKendry, T.
    Masaquel, A. S.
    Shapouri, S.
    Sail, K.
    Durno, N.
    Mato, A.
    VALUE IN HEALTH, 2019, 22 : S78 - S79
  • [13] Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapse/refractory chronic lymphocytic leukaemia
    Bastus, N. Coll
    Bennison, C.
    Durno, N.
    Sail, K.
    Alexiou, D.
    Mato, A.
    Eyre, T. A.
    Follows, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 106 - 107
  • [14] Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain
    Moreno-Martinez, Estela
    de la Serna-Torroba, Javier
    Escudero-Vilaplana, Vicente
    Angel Hernandez-Rivas, Jose
    Sanchez-Cuervos, Marina
    Sanchez-Hernandez, Raquel
    FARMACIA HOSPITALARIA, 2022, 46 (03) : 121 - 132
  • [15] THE COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS FLUDARABINE FOR THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN MEXICO
    Bertwistle, D.
    Munakata, J.
    Wehler, E.
    Leyva, V
    Valencia, A.
    Hernandez, A.
    de la Torre, L.
    Gonzalez, L.
    VALUE IN HEALTH, 2013, 16 (07) : A409 - A409
  • [16] COST-EFFECTIVENESS OF OFATUMUMAB PLUS CHLORAMBUCIL IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN CANADA
    Herring, W.
    Pearson, I
    Purser, M.
    Nakhaipour, H. R.
    Haiderali, A.
    Wolowacz, S.
    Jayasundara, K.
    VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [17] Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia
    Alrawashdh, Neda
    McBride, Ali
    Erstad, Brian
    Sweasy, Joann
    Persky, Daniel O.
    Abraham, Ivo
    VALUE IN HEALTH, 2022, 25 (10) : 1685 - 1695
  • [18] COST-EFFECTIVENESS OF OFATUMUMAB PLUS CHLORAMBUCIL IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
    Pearson, I., V
    Hawe, E.
    Zuluaga, S.
    Wolowacz, S.
    Haiderali, A.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [19] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [20] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
    Cho, Sang Kyu
    Manzoor, Beenish
    Sail, Kavita
    Ravelo, Arliene
    Shapouri, Sheila
    Sharmokh, Simon
    Kapustyan, Tatyana
    Johnson, Scott
    Parise, Helene
    Virabhak, Suchin
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57
12345